Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/08971900211002353 http://scihub22266oqcxt.onion/10.1177/08971900211002353 33736526!ä!33736526 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Pharm+Pract 2022 ; 35 (4): 587-592 Nephropedia Template TP {{tp|p=33736526|t=2022. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series |pdf=|usr=}}{{33736526}} gab.com Text Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series JO: J Pharm Pract http://www.kidney.de/pget.php?&tw=1&pmid=33736526 #FOAvip OBJECTIVE: To evaluate the use of tocilizumab in a community hospital setting for critically ill patients with severe COVID-19. DESIGN: A retrospective case series. SETTING: Five community hospitals within 1 urban health system. PATIENTS: Adult patients whom received tocilizumab between March 27th, 2020 to April 30th, 2020 for severe COVID-19. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Sixteen patients in total were evaluated from the 5 community hospitals. The mean (+/- SD) age of the patients was 53.9 +/- 9.2 years, 56% were men, and the most common comorbidities present on admission were hypertension (31%) and diabetes mellitus (25%). All patients received at least 1 other treatment modality for COVID-19 (steroids, hydroxychloroquine, or convaslescent plasma). Additionally, all patients on admission to intensive care units had severe COVID-19 with 56% requiring mechanical ventilation with a pre-tocilizumab median (IQR) Pao(2): Fio(2) of 84 (69 - 108.6), 19% requiring vasopressor support, and inflammatory markers (CRP, LDH, ferritin, and IL-6) were elevated. The median (IQR) tocilizumab dose was 400 mg (400-600) which correlated with a weight-based mean (+/- SD) dose of 5.4 mg/kg +/- 1.3. Of the 16 patients that received tocilizumab, 8 (50%) were discharged home, 7 (44%) died, and 1 (6%) was still hospitalized at the end of data collection. Patients who died were more likely to be older 62 +/- 2 years, female (57%), had a higher rate of mechanical ventilation (86%) and vasopressors (43%) use at baseline, and had a higher median (IQR) IL-6 level prior to tocilizumab administration 550 pg/mL (IQR 83-1924). There were no reported adverse drug reactions reported after the administration of tocilizumab for any patient. CONCLUSIONS: Our findings do not support the effectiveness of tocilizumab in treatment of severe COVID-19 infection in critically ill patients. Twit Text FOAVip Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series ????J Pharm Pract http://www.kidney.de/pget.php?&tw=1&pmid=33736526 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33736526 #FOAvip English Wikipedia <ref>{{Cite pmid|33736526}}</ref> Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series #MMPMID33736526 McKenzie MG; Lee YM; Mathew J; Anderson M; Vo AT; Akinyele S; Narayanan M J Pharm Pract 2022[Aug]; 35 (4): 587-592 PMID33736526show ga OBJECTIVE: To evaluate the use of tocilizumab in a community hospital setting for critically ill patients with severe COVID-19. DESIGN: A retrospective case series. SETTING: Five community hospitals within 1 urban health system. PATIENTS: Adult patients whom received tocilizumab between March 27th, 2020 to April 30th, 2020 for severe COVID-19. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Sixteen patients in total were evaluated from the 5 community hospitals. The mean (+/- SD) age of the patients was 53.9 +/- 9.2 years, 56% were men, and the most common comorbidities present on admission were hypertension (31%) and diabetes mellitus (25%). All patients received at least 1 other treatment modality for COVID-19 (steroids, hydroxychloroquine, or convaslescent plasma). Additionally, all patients on admission to intensive care units had severe COVID-19 with 56% requiring mechanical ventilation with a pre-tocilizumab median (IQR) Pao(2): Fio(2) of 84 (69 - 108.6), 19% requiring vasopressor support, and inflammatory markers (CRP, LDH, ferritin, and IL-6) were elevated. The median (IQR) tocilizumab dose was 400 mg (400-600) which correlated with a weight-based mean (+/- SD) dose of 5.4 mg/kg +/- 1.3. Of the 16 patients that received tocilizumab, 8 (50%) were discharged home, 7 (44%) died, and 1 (6%) was still hospitalized at the end of data collection. Patients who died were more likely to be older 62 +/- 2 years, female (57%), had a higher rate of mechanical ventilation (86%) and vasopressors (43%) use at baseline, and had a higher median (IQR) IL-6 level prior to tocilizumab administration 550 pg/mL (IQR 83-1924). There were no reported adverse drug reactions reported after the administration of tocilizumab for any patient. CONCLUSIONS: Our findings do not support the effectiveness of tocilizumab in treatment of severe COVID-19 infection in critically ill patients. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Antibodies, Monoclonal, Humanized[MESH] |Critical Illness/therapy[MESH] |Female[MESH] |Hospitals, Community[MESH] |Humans[MESH] |Interleukin-6[MESH] |Male[MESH] |Middle Aged[MESH] |Respiration, Artificial[MESH] |Retrospective Studies[MESH]Tocilizumab for the Critically Ill With Severe COVID-19: A Community H(epmc).pdf DeepDyve Pubget Overpricing